Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $6.26 Million - $7.49 Million
51,000 Added 3.76%
1,407,200 $201 Million
Q1 2024

May 15, 2024

BUY
$102.11 - $135.92 $43.2 Million - $57.5 Million
422,900 Added 45.31%
1,356,200 $174 Million
Q4 2023

Feb 14, 2024

SELL
$87.78 - $105.45 $4.94 Million - $5.94 Million
-56,300 Reduced 5.69%
933,300 $96.5 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $43.1 Million - $94.5 Million
473,400 Added 91.71%
989,600 $90 Million
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $21.3 Million - $23.6 Million
136,800 Added 36.06%
516,200 $83.5 Million
Q1 2023

May 15, 2023

SELL
$132.34 - $159.14 $4.21 Million - $5.06 Million
-31,800 Reduced 7.73%
379,400 $60.4 Million
Q4 2022

Feb 14, 2023

SELL
$102.55 - $135.33 $1.88 Million - $2.48 Million
-18,300 Reduced 4.26%
411,200 $55.6 Million
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $17.9 Million - $22 Million
187,900 Added 77.77%
429,500 $42.8 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $253B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.